HB Fuller Share Price Today

H.B. Fuller targets $50M incremental savings by 2030 via Quantum Leap

H.B. Fuller confirms on track for $25 million in run-rate cost savings by end of FY26. New guidance projects $50 million in incremental annual savings by 2030. Global manufacturing footprint reduced to 64 sites, targeting 55 by 2030. Capital spending expected to drop below $25 million in 2027 after $100 million investment.

UBS lowers H.B. Fuller price target to $55, maintains Neutral rating

UBS lowers H.B. Fuller price target from $69 to $55. Analyst Lucas Beaumont maintains a Neutral rating on the stock. The price target reduction amounts to a $14 decrease.

H.B. Fuller rejects $1.2B-$1.4B bid for adhesive unit

H.B. Fuller Board rejected Ancora's $1.2B-$1.4B cash bid for Building Adhesive Solutions. Rejection cited undervaluation of organic growth and Project Quantum Leap upside. Company plans market check for less integral segments to generate deleveraging proceeds. Market check completion targeted for year-end 2026.

H.B. Fuller prices $850M debt offering for AMS acquisition

H.B. Fuller priced $850 million in 7.625% senior unsecured notes due 2034. Proceeds will fund the Advanced Medical Solutions Group acquisition and refinance existing debt. $450 million of the notes are subject to mandatory redemption if the acquisition fails by June 25, 2027. The notes were issued at 100% of their principal amount with semi-annual interest payments.

H.B. Fuller declares $0.245 per share quarterly cash dividend

H.B. Fuller declared a quarterly cash dividend of $0.2450 per share. Payment date set for October 29, 2026 for shareholders of record on October 15, 2026. Company has paid quarterly dividends for 58 consecutive years.

Ancora raises bid for H.B. Fuller building unit to $1.4 billion

Ancora raised its bid for H.B. Fuller's Building Adhesive Solutions unit to $1.2-$1.4 billion. The new offer is backed by a "highly confident" financing letter from Fortress Investment Group. The bid values the unit at 8.5x-9.9x LTM EBITDA, representing ~50% of H.B. Fuller's equity value. H.B. Fuller previously rejected an August bid of $1.1-$1.2 billion as undervaluing the business. Management cites significant operational dis-synergies but remains open to valuation-driven divestiture.